Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$16.20 USD
-0.03 (-0.18%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $16.20 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVDL 16.20 -0.03(-0.18%)
Will AVDL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AVDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVDL
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
HUM Expands Musculoskeletal Care Access With New Value-Based Tie-Ups
AVDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Avadel (AVDL) Have the Potential to Rally 27.95% as Wall Street Analysts Expect?
Acadia & ECU Health Expand Behavioral Care Access in North Carolina
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
Other News for AVDL
Doji - Bearish? appears for AVDL after 0.18% move
Stochastic Reached Overbought appears for AVDL after 3.64% move
Craig-Hallum Sticks to Their Buy Rating for Avadel Pharmaceuticals (AVDL)
Is AVDL preparing for a move? Bollinger Band Squeeze shows up after gaining 1.62%
Wells Fargo Reaffirms Their Hold Rating on Avadel Pharmaceuticals (AVDL)